It’s 2020, and for the first time in its 72-year history, the American Academy of Neurology has cancelled its annual meeting because of the COVID-19 pandemic. But that does not mean we (BrainWaves producers, not the AAN) can’t provide a few major updates to advances in neurology and neurotherapeutics! This week on the program, Jim Siegler is joined by Dr. Sammita Satyanarayan (Stanford) on a whirlwind tour of some of the latest advances in neurology from this past year. Enjoy!

** IF YOU’RE TAKING YOUR NEUROLOGY BOARDS THIS SUMMER, CHECK OUT THE PENN NEUROLOGY BOARD REVIEW COURSE AT https://upenn.cloud-cme.com/default.aspx?P=5&EID=65373. AND FOR A DISCOUNTED RATE ON THE ONLINE OR STREAMING RESOURCES, USE PROMO CODE ‘WAVES2020’. **

DISCLAIMER: BrainWaves: A Neurology Podcast is not a product of the American Academy of Neurology (AAN) or its affiliates. Any content discussed on the program does not reflect the opinions of the AAN or its leadership nor does it contain any copyrighted material by the AAN or its affiliates. This program is neither published in collaboration with the AAN nor is it intended to plagiarize any content or programming of the AAN or its affiliates. The opinions discussed in this program are those of the producers and are not reflective of their employers or affiliates. This episode was produced by Sammita Satyanarayan and James E. Siegler. Music courtesy of E’s Jammy Jams, Lee Roosevere, Rui, and Steve Combs. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast.

REFERENCES

1. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: Cardiovascular safety profile of triptans (5-ht agonists) in the acute treatment of migraine. Headache. 2004;44:414-425
2. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62:563-568
3. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. The New England journal of medicine. 2018;378:1573-1582
4. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018;91:e2222-e2232
5. Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. The New England journal of medicine. 2019;380:1597-1605
6. Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-1904
7. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with huntington's disease. The New England journal of medicine. 2019;380:2307-2316
8. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: The extend-ia tnk part 2 randomized clinical trial. JAMA : the journal of the American Medical Association. 2020. Epub ahead of print.